Lupin Limited (NSE: LUPIN)

India flag India · Delayed Price · Currency is INR
2,150.70
-12.15 (-0.56%)
Dec 20, 2024, 3:30 PM IST
69.32%
Market Cap 979.71B
Revenue (ttm) 214.31B
Net Income (ttm) 26.26B
Shares Out n/a
EPS (ttm) 57.41
PE Ratio 37.30
Forward PE n/a
Dividend 8.00 (0.37%)
Ex-Dividend Date Jul 16, 2024
Volume 1,111,298
Open 2,165.00
Previous Close 2,162.85
Day's Range 2,138.40 - 2,177.75
52-Week Range 1,252.55 - 2,312.00
Beta 0.59
Analysts n/a
Price Target n/a
Earnings Date Feb 5, 2025

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv... [Read more]

Sector Healthcare
Founded 1968
Employees 19,210
Stock Exchange National Stock Exchange of India
Ticker Symbol LUPIN
Full Company Profile

Financial Performance

In 2023, Lupin's revenue was 200.11 billion, an increase of 20.25% compared to the previous year's 166.42 billion. Earnings were 19.14 billion, an increase of 345.15%.

Financial Statements

News

Lupin confirms tentative US FDA approval for Type-2 Diabetes drug Janumet generic

Lupin Limited has clarified reports regarding a recent news item about the company receiving US FDA approval. The company confirmed that it has received tentative approval from the US FDA for its gene...

20 days ago - Business Upturn

Lupin and NAPCON hold walkathon for lung health

Lupin Limited and the National Conference of Pulmonary Diseases (NAPCON) 2024 hosted the second ‘A Step Towards Healthy Lungs Walkathon’ at the Raceco.

24 days ago - The Times of India

Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally

Lupin Ltd and Aurobindo Pharma Ltd stocks moved upwards in early trade, with Lupin’s shares trading at ₹2,194.50, marking a 0.58% increase, while Aurobindo Pharma stood at ₹1,399.50, up by 0.18% as of...

6 weeks ago - Business Upturn

Lupin launches first generic of Pred Forte in United States

Global pharma major Lupin Limited (Lupin) has recently informed exchanges that the company has launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in ...

2 months ago - Business Upturn

Lupin signs non-exclusive patent license agreement with Takeda to commercialize Vonoprazan in India

Lupin Limited has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in India. Under this agreement, Lupin will market...

3 months ago - Business Upturn